"Imatinib Mesylate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
| Descriptor ID |
D000068877
|
| MeSH Number(s) |
D02.065.277.456 D02.241.223.100.100.435 D02.455.426.559.389.127.085.465 D03.383.606.405 D03.383.742.349
|
| Concept/Terms |
Imatinib Mesylate- Imatinib Mesylate
- Mesylate, Imatinib
- Imatinib Methanesulfonate
- Methanesulfonate, Imatinib
Imatinib- Imatinib
- Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
|
Below are MeSH descriptors whose meaning is more general than "Imatinib Mesylate".
Below are MeSH descriptors whose meaning is more specific than "Imatinib Mesylate".
This graph shows the total number of publications written about "Imatinib Mesylate" by people in this website by year, and whether "Imatinib Mesylate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 11 | 11 |
| 2004 | 0 | 7 | 7 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 6 | 6 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 5 | 5 |
| 2009 | 0 | 9 | 9 |
| 2010 | 0 | 9 | 9 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 9 | 9 |
| 2013 | 0 | 6 | 6 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 3 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 2 | 4 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imatinib Mesylate" by people in Profiles.
-
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 Sep 12; 391(10):885-898.
-
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. 2021 11; 157:428-440.
-
New strategies for targeting kinase networks in cancer. J Biol Chem. 2021 10; 297(4):101128.
-
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 02; 35(2):440-453.
-
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 01; 7(1):42-50.
-
Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected? Leuk Lymphoma. 2020 12; 61(12):2783-2784.
-
Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy. Am J Med Genet A. 2020 07; 182(7):1576-1591.
-
"All Our Wisdom is Stored in the Trees" - Degrading BCR-ABL with Berberis Vulgaris. Clin Cancer Res. 2020 08 01; 26(15):3899-3900.
-
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 04; 34(4):966-984.
-
Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652.